RxDoctor Payments Data

Anita Shankar, MD

Internal Medicine · Southlake, TXNPI 1831446855

Payments from drug & device makers

$1,248in general payments, 2019–2025

Across 33 payments — averaging $37.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$693
  • Boehringer Ingelheim$100
  • Novo Nordisk$65
  • Merck$39
  • AbbVie$36
  • Takeda Pharmaceuticals U.S.A., Inc.$35
  • plus $280 from 14 others

What the payments were for

  • Food & beverage$1,248100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,248 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$87,411
Medicare patients
236
Services billed
1,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$83,668
EliquisApixaban24$24,433
JardianceEmpagliflozin11$15,058
Levothyroxine Sodium278$3,070
SynthroidLevothyroxine Sodium38$2,763
Atorvastatin Calcium246$1,943
Rosuvastatin Calcium179$1,775
Fluticasone Propionate99$1,764
Azelastine Hcl59$1,581
Amlodipine-ValsartanAmlodipine Besylate/Valsartan11$1,358
Albuterol Sulfate HfaAlbuterol Sulfate46$1,335
Lisinopril158$1,112
Trazodone Hcl85$915
Bupropion XlBupropion Hcl34$890
Montelukast Sodium88$880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$65$83,66868 claims
PfizerEliquis$31$24,43324 claims
Boehringer IngelheimJardiance$100$15,05811 claims
AbbVieSynthroid$36$2,76338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Southlake

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →